AstraZeneca, Taj Pharma launch Gemcitabine HCI for Injection in US
AstraZeneca Pharmaceuticals and Taj Pharmaceuticals, an India-based manufacturer of generic drugs as well as specialty pharmaceuticals and active pharmaceutical ingredients, have commercially launched Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials in the US.
Gemcitabine HCI for Injection, the generic version of Gemcitabine HCI, was launched pursuant to a commercialization, manufacture and supply agreement signed by AstraZeneca and Taj Pharmaceuticals, indiacompanynews.com reported.
As per the agreement, AstraZeneca will manufacture Gemcitabine HCI for Injection and will receive a license to market the product within the India-based firm's 180-day exclusivity.
Taj Pharma will get a royalty during the manufacturing period.
Indiacompanynews.com has quoted Taj Pharmaceuticals Generics senior vice president Ajay Sodhi sa saying that the agreement allows them to accelerate the availability of the important generic product Gemcitabine HCI.
Feb 08, 2011